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Over the past 20 years the understanding of human
leukocyte antigen (HLA) diversity and the impact of
HLA matching on unrelated donor hematopoietic
stem cell transplantation (HSCT) outcomes have
evolved greatly. The National Marrow Donor Pro-
gram (NMDP) has been intimately involved in moni-
toring, developing, and applying new methodologies
forHLA testing, data capture techniques, and data rep-
resentation methods to ensure that HLA typing of
newly registered potential volunteer HSC donors and
donors identified as potential matches is of the highest
quality and accuracy for the benefit of searching pa-
tients. The following commentary provides an over-
view of the evolution of HLA typing for the NMDP
Registry over the 20-year history of the organization.
Of special note are the methodologic changes and
the development of high-quality HLA data capture,
interpretation, and storage systems that have made sig-
nificant enhancements to the NMDP search algo-
rithm, yielding more efficient and accurate unrelated
donor and cord blood unit (CBU) searches. In addi-
tion, the application of these strategies to the NMDP
Research Sample Repository of donor-recipient pairs
has allowed the completion of several critical retro-
spective analyses of HLA match and outcome.MEASURING COMPATIBILITY: FROM CELLULAR ASSAYS
TO DNA-BASED TECHNIQUES
During the first 9 years of theNMDPRegistry, the
minimum level of HLA typing required to list a newly
registered volunteer HSC donor was serologically de-
fined HLA-A and -B typing, with the majority of the
testing performed by laboratories that were selected
by the donor center network staff. HLA-DR typing
was not routinely performed because of its difficulty
and expense. Serologic typing utilizes human alloanti-
sera to identify proteins (antigens) on the surface of
lymphocytes. This typing method is known to have
many limitations, including the requirement for viable
cells, the lack of appropriate sera to type antigens more
commonly found in minority populations, and rela-
tively high discrepancy rates [1]. Because alloantisera
were typically derived from a specific racial/ethnic
population, the methodology was less than optimal
for testing a racially/ethnically diverse population tar-
geted for inclusion on a volunteer donor registry. In
addition to serologic matching, donor/recipient com-
patibility for HLA class II types was typically assessed
using the mixed lymphocyte culture (MLC) assay.
This cellular assay was time consuming, required large
volumes of blood, and was influenced by the health
of the recipient and the viability of donor cells often37
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recognized limitations of serologic and MLC typing
methods led many within the HLA community to
seek more robust reproducible methodologies to
more accurately assess the compatibility of donor/re-
cipient pairs and to ensure high-quality testing results
that could stand the test of time on a registry of volun-
teer HSC donors.
The International Histocompatibility Workshops
(IHWS) of the mid-1980s through the mid-1990s ex-
pended significant energy to refine DNA-based HLA
typing methods. A major leap forward in DNA-based
HLA typing technology came with the introduction
of the polymerase chain reaction (PCR) [3] and stud-
ies demonstrating the feasibility of HLA typing via
PCR and sequence-specific oligonucleotide probes
(SSOP) [4,5]. This assay employed gene amplification
and identification of oligotypes by the hybridization
of single-stranded DNA probes to sites of DNA
sequence variation (i.e., polymorphisms). The 11th
workshop evaluated the ability to assign HLA alleles
using PCR-SSOP DNA-based methods [6]. In addi-
tion, other DNA-based methodologies including
sequence-specific primers (SSP), PCR heteroduplex
formation, and direct sequencing assays were de-
scribed, adding to the diverse repertoire of tech-
niques. The development of DNA methods for class
II typing allowed HLA laboratories to eliminate the
MLC as a means of evaluating donor/recipient com-
patibility for class II loci.
During the development of HLA typing method-
ologies, an improvement in DNA sequencing method-
ologies resulted in the identification of new HLA
alleles. Eighty-seven new HLA alleles were described
by the 11th workshop and published in the report on
Nomenclature for Factors of the HLA System, 1991
[7]. Since that time, the number of new alleles identi-
fied has continued to increase, so that today almost
2000 HLA alleles have been identified at the HLA-A,
-B, and -DRB1 loci. To address the continuous in-
crease in HLA diversity, robust sequencing strategies
were developed within NMDP research studies and
applied to patients and their potential donors to pro-
vide matching at high resolution and to develop
matching guidelines to improve outcome.
TRANSITIONING TO DNA-BASED TYPING FOR NMDP
REGISTRY VOLUNTEERS
The inadequacies of serologic typing and the ben-
efits of DNA-based typing were demonstrated in sev-
eral large studies spearheaded by the NMDP and the
C.W. Bill Young Department of DefenseMarrowDo-
nor Program, Naval Medical Research Institute (Cen-
ter since 1998) (Navy) during the early to late 1990s
following feasibility studies by the Navy. The first
studies were directed toward development of a reliableDNA-based typing system to discern HLA-DRB1/3/5
and -DQB1 oligotypes (groups of alleles defined by
a hybridization pattern with a panel of SSOP). As the
importance of DRB1 matching was demonstrated
through outcome studies [7], the traditional methods
for class II compatibility proved unreliable [2], and as
DNA-based typing for DRB1 became more routine
and cost effective, typing strategies changed to include
DRB1. In 1992, the NMDP initiated a Navy-sup-
ported prospective DNA testing program for DRB1
and, working with a team of HLA typing laboratories,
optimized approaches for large-volume testing. The
results of the effort were presented in 2 separate
reports from Ng et al. [8,9].
The first report detailed the initial 7 months of
typing activity utilizing SSOP techniques to test vol-
unteer donor samples [8]. Seven laboratories partici-
pated in the project, with many employing the
primers and probes described in the 11th IHWS and
others using locally developed primer and probe sets.
Laboratories received shipments of volunteer donor
samples intermingled with identically labeled ‘‘blind’’
quality control samples (samples previously typed by
the Navy/NMDP). The group assessed the sensitivity
of the assay (probability of testing positive if the type
was present) and specificity (probability of testing neg-
ative if the type was not present). The study found cor-
rect assignment of DRB1/3/4 and DQB1 oligotypes in
99% and 98%, respectively, from a cohort of 1652
blind quality control samples. The results were very
impressive, especially because the quality control sam-
ples were intermingled with over 9000 volunteer do-
nor samples and were not given any special attention
during the testing process. This analysis was the first
definitive demonstration that PCR/SSOPHLA typing
was feasible on a large scale and was highly specific,
accurate, and reliable.
The follow-up analysis detailed the results of the
second year of the project [9]. The 7 participating lab-
oratories completed an additional 62,216HLA-DRB1/
3/4 and -DQB1 typings (57,580 donors samples and
4636 blind quality control samples). The average per-
cent of correctly classified HLA oligotypes based on
9244 DRB1 and 7244 DQB1 assignments was 99.8%
(range 99.4%-100%) and 99.8% (range 99.6%-
100%), respectively.The resultswere again remarkable
considering the increased typing volume from the first
phase of the project and an increase in the overall reso-
lution of the typing, that is, additional oligonucleotide
probes added to the typing kit.
Following up on the success of the implementation
of class II typing by DNA-based methods, the NMDP
helped lead an effort to develop a testing system for
HLA-A and -B. The application of DNA-based
HLA typing for HLA-A and -B was further assessed
for accuracy, and validated in 2 large-scale analyses
by Hurley et al. [10] and Noreen et al. [1]. The Hurley
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DNA-based typing by assessing the quality control
testing rates from July 1997 to June 1998 of an
NMDP typing project in a manner similar to the ap-
proach used for class II testing assessment [10]. A total
of 64,180 volunteer donor samples and over 11,400
quality control samples were tested. The authors ob-
served an error rate of 1.1% and 1.9% for HLA-A
and -B, respectively, demonstrating that the SSP and
PCR/SSOP techniques employed in the testing were
robust.
Noreen et al. [1] went on to validate the accuracy
of the techniques through assessment of volunteer do-
nors tested in parallel with serologic techniques. Sero-
logic typing was performed between 1993 and 1997
on 42,160 volunteer donors of which 99.9% were
from U.S. minority population groups. The analysis
was conducted in 2 phases. In phase I, DNA-based
typing was performed without knowledge of the pre-
vious serologic assignments. The authors found dis-
crepancies between the serologic and DNA-based
assignments in 24% of the volunteer donor samples.
In phase II, a random sampling strategy was used to
select a statistically significant number of individuals
for repeat DNA typing from each of the categorized
discrepant groups. The repeat DNA-based testing
was correct for approximately 99% of HLA-A assign-
ments, over 98% for HLA-B and .97% for HLA-A
and -B combined. This analysis provided a compre-
hensive validation of the ability of DNA-based typing
to define all known low-resolution types and sup-
ported transition of registry typing protocols to
DNA-based approaches.
In January 2000, the NMDP merged the separate
class I and II typing programs based on the results of
a Health Resources and Service Administration and
Office of Naval Research sponsored study completed
in 1999 by Kollman et al. [11]. This study concluded
that recruiting new volunteers and typing them for
only HLA-A and -B was not a cost-effective strategy.
Although initially less expensive per volunteer, a re-
gression model estimated that a searching patient
with a matched volunteer was nearly 5 times more
likely to proceed to transplantation if their match
was already fully typed in the Registry. These data,
combined with cost efficiencies that could be achieved
by the contract laboratories and repositories by ship-
ping the sample only once, extracting DNA once,
and reporting once for each new donor, supported
the decision.
The development of the NMDP registry typing
programs relied on key contributions from the
Navy, NMDP Histocompatibility Committee, the
participating laboratory principal investigators, and
reagent/typing system manufacturers. Periodic meet-
ings were held with the principal investigators to re-
view the functionality of the typing methodologiesand to discuss modifications to the reagent set or
processing protocols to improve resolution or robust-
ness of the system. Significant effort was placed on
evaluating the typing reagents to produce robust re-
sults and increased resolution aimed at distinguishing
among common HLA alleles [12]. Reagents that gave
weak or inconsistent signals were redesigned either
in-house (at 1 of the HLA typing laboratories) or by
the vendor to improve the accuracy of testing. The
NMDP continues to follow this collaborative model
to ensure that the registry typing program continues
to generate the most accurate and highest resolution
results possible.
IMPROVING ACCURACY, QUALITY, PRICE, AND
RESOLUTION OF HLA ASSIGNMENTS
The impact of the change from serologic to DNA-
based testing is best illustrated by the increasing
accuracy when the initial HLA typing of a volunteer
is compared to the HLA typing obtained when that
donor is retested as a potentialHSCdonor for a search-
ing patient. Figure 1 shows the change in the number
of samples discrepant at the time of confirmatory
typing with the typing obtained at recruitment [13].
Although it is not possible to distinguish discrepancies
because of errors in recruitment typing from other
sources of errors, that is, changes in nomenclature or
higher resolution reagents, it is clear that the discrep-
ancies are clearly decreasing over time for all 3 HLA
loci evaluated. The increased accuracy of the DNA
typing has had a significant positive impact on the
patient search process. In minority race donors
recruited from 1991 to 1996, the rate of discrepancy
from recruitment typing to CT typing was approxi-
mately 10%. For minority donors recruited and typed
in the years of 1997 to 2001, the rate of uncovering any
type of HLA-A, -B, or -DRB1 discrepancy with CT
typing dropped to 3.5%.
Figure 1. The percent of confirmatory typing results that were in-
consistent with the volunteer donor’s HLA typing on the NMDP
file by year of recruitment. In most cases, the typing in the file was
obtained at the time of recruitment. It is not possible to attribute
the source of error to the recruitment typing versus other sources
of errors.
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ment typing costs over the past 10 years is illustrated
in Figure 2. A major reason for the large decline in
the late 1990s was the transition from separate class
I and II typing programs to a combined program
that utilized a single sample for the testing. Addition-
ally, the introduction of new typing systems, that is,
bead-based SSOP, decreased the labor-intensive na-
ture of the testing and was amenable to automation.
Concomitant to the reduction in pricing, signifi-
cant increases in resolution for HLA-A, -B, and
-DRB1 were achieved over the 10-year time frame.
Initially, in 1999, DNA-based typing resolution was
similar to the level achieved by serologic typing
(e.g., A*01XX 5 A*0101, 0102, 0103, 0104, 0105
equivalent to A1). By the end of 2006, the resolution
was at ‘‘high/intermediate,’’ where the laboratories
reported at either the allele level (e.g., A*0104) or uti-
lized oligotypes with reduced combinations of alleles
(e.g., A*01AF 5 A*0101 and A*0104). Within the
same time frame the number of alleles that had to
be considered (and the resulting increase in potential
alternative allele combinations that needed to be
tested for and resolved) in the typing strategy for class
I grew from 430 to 1180 and for DRB1 from 226 to
511.
The higher level of resolution in the HLA assign-
ments allows transplant centers to more rapidly nar-
row the search and identify the best potentially allele
matched HSC donors. The high accuracy rate and
the decreased cost per sample demonstrate the accom-
plishment of optimizing DNA typing technology for
high-volume testing. In addition, testing initially re-
quired up to 60 days, and now the majority of testing
is complete in 14 days or less. The shortened testing
time frames help to ensure that new donors, particu-
larly those recruited through patient-focused drives,
are registered quickly. The decreased cost positively
impacts the ability to add higher numbers of new do-
nors to the Registry, therefore increasing the probabil-
ity of searching patients finding suitably matched
unrelated donors.
Figure 2.Declining Price of Registry HLA-A, B, DRB1 typing. The
change in HLA-A, -B, -DRB1 recruitment typing cost for the
NMDP registry over the past 10 years.CHANGING SAMPLE REQUIREMENTS AND CENTRALIZED
REPOSITORIES
The transition from serologic to DNA-based
methods for HLA testing had profound effects on
the NMDP’s volunteer donor sample collection and
distribution network. The need for fresh viable leuko-
cytes for serologic testing necessitated the direct ship-
ment of samples to typing laboratories to ensure the
highest sample quality possible. The introduction of
DNA-based testing made feasible the archiving of vol-
unteer donor samples in centralized repositories to
standardize processing, labeling, and distribution,
and to facilitate long-term storage for repeat testing
or step-wise testing upgrades. The NMDP established
2 frozen blood sample repositories to handle the large
volume of donor recruitment samples. Later, process-
ing and storage was centralized at an NMDP-operated
donor sample repository in Minneapolis.
Sample collection and storage procedures were
constantly evaluated to ensure that the stored samples
were the most cost-effective possible. In the late 1990s,
the NMDP began to explore the potential to begin
a transition to collecting, storing, andHLA testing po-
tential HSC donor blood samples dried on filter paper
cards to eliminate the need for frozen blood storage.
The groundwork for the effort was developed from
earlier studies evaluating the technical aspects of the
sample collection process, long-term sample stability,
and the accuracy and precision of DNA-based HLA
typing protocols utilizing 2 uniquely different filter
paper cards [14]. In August 2002, the NMDP recruit-
ment network was transitioned to collect small quanti-
ties of blood by finger stick with the expectation that
phlebotomists would not be required, and therefore,
a significant cost savings could be achieved. When
these cost savings were not realized because of require-
ments in many states that all blood samples be col-
lected by licensed phlebotomists, another method,
collection of donor DNA by buccal swabs, was evalu-
ated and implemented in May 2006. These swabs can
be more easily shipped and can be stored at room
temperature, further reducing cost.
DEVELOPING ELECTRONIC HLA DATA REPORTING,
INTERPRETATION, AND CURATION SYSTEMS
It was recognized at the inception of DNA-based
HLA typing that the optimal approach to avoid the
complexities created by the addition of new HLA al-
leles over time would be to record and utilize the probe
and primer hybridization data (i.e., DNA nucleotide
sequence polymorphisms) in addition to the inter-
pretedHLA type (i.e., HLA oligotype) [15]. Recording
theHLA typing data (i.e., primary data) on new donors
as polymorphisms present, absent, or not tested would
eliminate outdating of oligotypes and facilitate selec-
tion of donors whomay be possiblematches for further
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sulting from donor typings, the NMDP had to develop
information technology and communication systems
capable of accepting and managing the typing data at
a subnomenclature representation. With funding sup-
port and guidance from the Navy, computer infra-
structure to manage primary typing data reported by
laboratories in addition to the interpreted HLA
oligotypes used on search reports was developed and
implemented.
The utility of this approach was demonstrated in
a study led byMaiers et al. [12], where the authors eval-
uated DNA-based HLA-DRB1 assignments reported
from 371,187 donors. All typing results and probe
hybridization patterns were electronically reported to
the NMDP. The hybridization patterns were reinter-
preted using a computer program and compared to
the original results. There was a high correlation be-
tween the typing assignments between the computer
system and the submitting laboratory. The stored
data was later reinterpreted using an allele list defined
approximately a year after the typings were submitted
and the authors found that 74% of the interpretations
of primary data leading to HLA-DRB1 assignments
would have been altered by newly described alleles.
The findings of the analysis clearly demonstrated the
utility of storing polymorphic DNA sequences present
or absent rather than interpreted typing results.
The original systems developed by the NMDP re-
quired consistency in message formatting and reagent
sets. In more recent years, the systems were enhanced
to accept primary data frommultiple types of method-
ologies including SSOP, SSP, and sequence-based typ-
ing (SBT) from kits developed by multiple vendors.
The NMDP established confidentiality agreements
with all participating reagent vendors to allow the pop-
ulation of a database with their proprietary nucleotide
sequences of the probes and primers, which in turn, al-
lowed on-site reinterpretation of the primary data into
HLA oligotypes. This acted as an additional measure
of quality control and allowed for the eventual integra-
tion of these data into the enhanced matching algo-
rithm, HapLogicSM (described below).
INTEGRATING SEROLOGIC AND DNA TYPING
ASSIGNMENTS FOR MATCHING
Today, 58.9% of volunteer donors on the NMDP
Registry have HLA assignments determined by
DNA-based methodologies, 23.3% have a mixture of
serologic and DNA assignments, and 17.8% have
only serologic assignments. To include both the sero-
logically typed volunteers and the more recently
DNA-typed volunteers in the search for a specific pa-
tient, NMDP has had to develop a strategy to compare
results obtained with various typing methodologies to
identify matched donors. These efforts led to aninternational collaboration to collect and correlate
serologic assignments with DNA oligotypes and indi-
vidual alleles. Initial efforts employed the use of the
Expectation Maximization (EM) algorithm to evaluate
NMDP volunteers who had both DNA and corre-
sponding serologic HLA assignments. This innovative
application of the EM algorithm to predict the most
likely serologic association, along with information
from the UCLA International Cell Exchange and
results from individual HLA typing laboratories, re-
sulted in a serology to DNA ‘‘dictionary’’ that was first
published in 1997. This dictionary has become a refer-
ence work and is updated every few years [16-19].
In 2003, the NMDP enhanced the dictionary by
developing a neural network strategy to predict the se-
rologic assignments of HLA alleles lacking this infor-
mation. This study by Maiers et al. [20] used the
protein sequences of the many HLA antigens and their
known serologic associations in the prediction. This
bioinformatics strategy has been incorporated into
the latest serology-DNA dictionary. These studies
provide the information needed to populate tables
used by HapLogic to select potentially matched do-
nors for searching patients. It is also used by foreign
registries for their search algorithms. Most impor-
tantly, it is used as a resource by transplant centers
worldwide in the search for potentially matched
HSC donors.
THE NMDP MATCH ALGORITHM: HAPLOGIC
The transition to DNA-based HLA typing and the
development of sophisticated data processing systems
and serologic interpretation tables have all contributed
to the recent enhancements to theNMDPmatch algo-
rithm,HapLogic. Prior to the introduction of HapLo-
gic, to provide a consistent evaluation of all donors
regardless of typing method the serologic and DNA-
based results were converted to serologic equivalents
[21]. HapLogic employs the reverse strategy, convert-
ing serologic typings to lists of possible DNA geno-
types based on serology-DNA equivalency tables.
This strategy permits all of the data within the
NMDP registry to be converted to genotype lists for
use in donor and CBU searches. It allows reinterpreta-
tion of the genotype data to include newly described
alleles, and fully permits evaluation of which alleles ap-
pear in a genotype pair together when stored primary
data is available, which are distinct advantages over
the previously employed serologic equivalent match-
ing logic [22].
HapLogic also utilizes allele level haplotype fre-
quency data calculated from a donor data set repre-
senting the primary U.S. racial/ethnic groups. The
haplotype data are used to predict a probability score,
indicating the likelihood that a potentially matched
HSC donor or CBU will result in an allele match for
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in February 2006 provided predictions on a scale of 0%
to 99% for an HLA-A, -B, and -DRB1 allele match
at each locus and an overall prediction for a 6 of 6, 5
of 6, and 4 of 6 allele level match. The January 2008
release incorporated prediction scores for HLA-C
and -DQB1 to support donor and CBU selection for
additional loci important for transplant outcome.
Since the introduction of HapLogic, the NMDP has
noted a 30% reduction in the number of donors re-
quested for confirmatory typing, reflecting the utility
of the predictions to rapidly identify donors or CBUs
with the highest probability of matching the searching
patient.
However, even with the advances in the matching
algorithm, the increasing complexity of HLA assign-
ments and matching requirements requires that trans-
plant centers either acquire in-house HLA expertise or
rely on external support. The NMDP has developed
services that assist transplant centers with complex
adult volunteer HSC donor or CBU searches. In par-
ticular, the HLA Search Strategy Advice program uses
external and internal HLA experts to provide search
strategy recommendations to help identify the best
potentially matched stem cell source for a patient. In
addition to providing search strategy advice, the core
group of internal NMDP HLA experts rigorously
check quality control and validate enhancements to
HapLogic to help ensure the accuracy and utility of
all modifications. The NMDP is committed to further
enhancing HapLogic to simplify donor selection, but
for difficult searches HLA expertise will be required
for development of effective worldwide search
strategies.
GUIDING OPTIMAL DONOR SELECTION
In 1994, theNMDP initiated aNavy supported re-
search project aimed at retrospectively identifying the
HLA alleles carried by donor/recipient pairs banked in
the NMDP Research Sample Repository. The Repos-
itory was begun in 1987, and today contains biologic
samples from over 14,000 HSCT recipients and their
respective donors. The goals of the study were to
develop robust high-resolution typing methods for
HLA alleles and to determine the impact of HLA
matching for specific loci (HLA-A, B, C, DRB1/3/4/
5, DQA1, DQB1, DPA1, and DPB1) on transplant
outcome. The project was the first extensive applica-
tion of sequence-based typing to the HLA class I
alleles. The initial samples sets were typed blindly in
2 different laboratories to evaluate the reliability and
reproducibility of the results. During the testing of
the first 2800 pairs, typing discrepancies dropped dra-
matically as the testing strategies became more robust.
In the evaluation of HLA disparities between
donor and recipient in an initial 1775 pairs, 29%of 6 of 6 antigen matched transplant pairs were
observed to carry allele mismatches at HLA-A, -B,
and/or -DRB1, and 92% carried at least 1 allele mis-
match at 1 of the 8 HLA loci tested [23]. The typing
methodologies developed through this research study
were adopted by the HLA laboratories supporting
transplant programs. The refinements in high-
resolution HLA typing have enhanced the ability of
transplant centers to more completely characterize
patient alleles for a more effective HSC donor
search.
The donor-recipient HLA data were used in an
outcome study by Flomenberg et al. [24] to demon-
strate the importance of HLA-C matching. Based on
this information, the NMDP published guidelines
for matching in unrelated donor HSCT in 2003 [25].
Most recently, Lee et al. [26] evaluated an extended
dataset (N5 3857 pairs) and showed that a single mis-
match, antigen, or allele, at HLA- A, -B, -C, or -DRB1
conferred an increased relative risk for mortality of
1.25 (confidence interval [CI] 1.13-2.38, P\ .0001)
and a 9% decrease in patient survival at 1 year. Single
mismatches at HLA-DP or -DQ were not associated
with increased mortality in both studies. The guide-
lines incorporating these new results are updated in
this supplement (Bray R., Hurley C, Kamani N, et al.
National Marrow Donor Program HLA matching
guidelines for unrelated adult hematopoietic cell trans-
plants.) The donor/recipient HLA database also allows
the evaluation of permissive mismatching strategies.
One study by Wade et al. [27] determined that selec-
tion of a CREGmatched donor had no impact on out-
come, allowing wider latitude in mismatched donor
selection.
Although the donor/recipient HLA database cur-
rently includes over 11,000 pairs and the Repository
over 14,000 pairs, the population still yields limited
statistical power for the evaluation of HLA matching
in particular transplant situations. Therefore, the
database will need to continue to accrue pairs for the
assessment of HLA matching requirements for differ-
ent stem cell sources (marrow versus peripheral blood
versus umbilical cord blood), for different patient pop-
ulations (e.g., adult versus pediatric; malignant versus
nonmalignant disease; minorities) and evolving treat-
ment strategies (e.g., reduced intensity conditioning
[RIC]). The database is now routinely used as the de-
finitive source of HLA match assignments for all re-
search studies conducted through the NMDP and
the Center for International Blood and Marrow
Transplant Research.
OPTIMIZING COMPATIBILITY ASSESSMENT AND
OUTCOME: WHAT DOES THE FUTURE HOLD?
Over time, the operational systems in the laborato-
ries, in the repositories and at the NMDP have been
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efficiency. This has resulted in the development of cut-
ting edge information and data management systems,
implementation of laboratory robotic systems, and re-
fined repository storage systems. HLA typing resolu-
tion continues to improve, resulting in near allele
level typing for HLA-A, -B, and -DRB1 at donor reg-
istration. Increased efficiencies in testing may allow
the typing of additional HLA loci at recruitment or
more rapid typing for urgent cases.
Many research laboratories are developing new
competing approaches to DNA testing methods.
Most of this DNA research is focused on developing
whole genome testing, and these approaches are being
applied to identifying other histocompatibility loci.
The methods are likely to lower the cost of DNA anal-
ysis, making it practical to determine whether addi-
tional genetic matches or mismatches may cause
additional transplant risks across a potentially large
number of genes. As information on the importance
of other polymorphic genes in HSCT becomes avail-
able, testing strategies can be readily implemented by
the NMDP through its contract laboratory network.
One drawback to current high resolution typing
methods is the limitations in unambiguously identify-
ing patient and donor genotypes. Even Sanger-based
DNA sequencing produces data for both pairs of ho-
mologous chromosome sequences (e.g., HLA se-
quences from both the maternal and paternal genes)
in each test run unless the genes are separated either
physically or by allele specific amplification as part of
the laboratory test. Because of the high number of
HLA alleles that share sequence polymorphisms,
most tests result in multiple possible alternative geno-
types. The resolution of these alternative genotypes
requires additional laboratory tests that can be com-
plex, costly, and time consuming. DNA sequencing
methods currently being developed analyze loci from
single chromosomes independently and, if cost effec-
tive, will eliminate ambiguous typing results.
The potential advantage is low-cost unambiguous
allele level typing for all newly registered volunteers
and rapid allele level typing for all patients seeking
HSC donors. Physicians searching for a donor for
their patient will be able to identify the precise type
and closeness of match almost immediately from
a computer-based analysis of possible donors. Of
course, the donor must be approached to assure their
availability and to obtain a second sample to confirm
identity. Strategies to identify the HLA alleles present
in recipient and donor have resulted in better matching
and the ability to develop risk-adapted therapies for
mismatched transplantations, thus increasing trans-
plant as an option for more patients. The database of
donor/recipient HLA assignments and clinical out-
come will continue to support research studies aimed
at optimizing outcome.The complexity involved in optimal HLA match-
ing continues to drive the need for growth in the
genetic diversity on adult volunteer HSC donor and
CBU registries to supply appropriately matched stem
cell sources to searching patients. The logistic and
analytic methods required to rapidly identify the best
potential match from worldwide sources will continue
to evolve, and the NMDP will continue to develop
resources necessary to facilitate the process.
ACKNOWLEDGMENTS
The authors acknowledge the contributions of the
Navy, who provided the vision, and past and present
members of the NMDP Histocompatibility Commit-
tee, who continuously advised the development of
HLA typing systems and resources described in this
manuscript. The authors also recognize the incredible
contributions of the network of contract laboratories
and repositories that have supported the HLA typing
programs since the inception of the NMDP. In addi-
tion, the work described would not have been possible
without the dedicated past and present staff members
of the NMDP Scientific Services, Repository Services,
and Bioinformatics departments. Last, much of the
work described was generously supported through
grants from theHealth Resources and Services Admin-
istration and the Office of Naval Research. Any
opinions, findings, conclusions or recommendations
expressed in this manuscript are those of the author(s)
and do not necessarily reflect the views of the Health
Resources and Services Administration or the Office
of Naval Research.
Financial Disclosure: Drs. Spellman and Setterholm
are employees of the NMDP and have a financial
relationship with the NMDP, in that capacity as
employees. Drs. Noreen and Fernandez-Vin˜a are
consultants for the NMDP. Dr. Hurley is an unpaid
consultant for the NMDP. Drs. Maiers, Oudshoorn,
Petersdorf, Bray, Hartzman, and Ng have nothing to
disclose.
REFERENCES
1. Noreen HJ, Yu M, Setterholm M, et al. Validation of DNA-
based HLA-A and HLA-B testing of volunteers for a bone
marrow registry through parallel testing with serology. Tissue
Antigens. 2001;57:221-229.
2. Mickelson EM, Bartsch GE, Hansen JA, Dupont B. The MLC
assay as a test for HLA-D region compatibility between patients
and unrelated donors: results of a national marrow donor
program involving multiple centers. Tissue Antigens. 1993;42:
465-472.
3. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzy-
matic amplification of DNAwith a thermostableDNApolymer-
ase. Science. 1988;239:487-491.
4. Tiercy J-M,Gorski J, JeannetM,Mach B. Identification and dis-
tribution of three serologically undetected alleles of HLA-DR
44 S. Spellman et al.by oligonucleotide DNA typing analysis. Proc Natl Acad Sci USA.
1988;85:198-202.
5. Scharf SJ, Freidmann A, Steinman L, Brautbar C, Erlich HA.
Specific HLA-DQB and HLA-DRB1 alleles confer susceptibil-
ity to pemphigus vulgaris. Proc Natl Acad Sci USA. 1989;86:
6215-6219.
6. Tsuji K, Aizawa M, Sasazuki T. HLA 1991: proceedings of the
eleventh international histocompatibility workshop and confer-
ence. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991:
Proceedings of the Eleventh International Histocompatibility Work-
shop and Conference Held in Yokohoma, Japan, 6-13 November,
1991. New York: Oxford University Press, 1993.
7. Petersdorf EW, Longton GM, Anasetti C, et al. The signifi-
cance of HLA-DRB1 matching on clinical outcome after
HLA-A, B, DR identical unrelated donor marrow transplanta-
tion. Blood. 1995;86:1606-1613.
8. Ng J, Hurley CK, Baxter-Lowe LA, et al. Large-scale oligonu-
cleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly
accurate, specific, and reliable. Tissue Antigens. 1993;42:
473-479.
9. Ng J, Hurley CK, Carter C, et al. Large-scale DRB and DQB1
oligonucleotide typing for the NMDP Registry: progress report
from year 2. Tissue Antigens. 1996;47:21-26.
10. Hurley CK, Maiers M, Ng J, et al. Large-scale DNA-based typ-
ing of HLA-A and HLA-B at low resolution is highly accurate,
specific, and reliable. Tissue Antigens. 2000;55:352-358.
11. KollmanC, Abella E, Baitty RL, et al. Assessment of optimal size
and composition of the U.S. National Registry of hematopoietic
stem cell donors. Transplantation. 2004;78:89-95.
12. Maiers M, Hurley CK, Perlee L, et al. Maintaining updated
DNA-based HLA assignments in the National Marrow Donor
Program Bone Marrow Registry. Rev Immunogenet. 2000;2:
449-460.
13. Setterholm M, Maiers M, Coleman L, et al. HLA typing of vol-
unteers for a hematopoietic stem cell donor registry: ensuring
and maintaining quality of the NMDP Registry. ASHI Q Second
Q. 2005;29:50-52.
14. Setterholm M, Hegland J, Weis T, McKenna J, Brown M,
Kays P. Stability of blood spotted on filter paper for HLA-A,
B and DR typing. Hum Immunol. 1999;60:S140.
15. Hurley CK. Acquisition and use of DNA-based HLA typing
data in bone marrow registries. Tissue Antigens. 1997;49:
323-328.
16. Hurley CK, Schreuder GM, Marsh SG, Lau M, Middleton D,
Noreen H. The search for HLA-matched donors: a summary
of HLA-A*, -B*, -DRB1/3/4/5* alleles and their associationwith serologically defined HLA-A, -B, -DR antigens. Tissue
Antigens. 1997;50:401-418.
17. Schreuder GMTh, Hurley CK, Marsh SGE, et al. The HLA
dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5,
-DQB1 alleles and their association with serologically defined
HLA-A, -B, -C, -DR and –DQ antigens. Tissue Antigens. 1999;
54:409-437.
18. Schreuder GMTh, Hurley CK, Marsh SGE, et al. The HLA
Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5,
-DQB1 alleles and their association with serologically defined
HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens. 2001;
58:109-140.
19. Schreuder GM, Hurley CK, Marsh SGE, et al. The HLA dic-
tionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/4/5 and
-DQB1 alleles and their association with serologically defined
HLA-A, -B, -C, -DR and -DQ antigens. Published concur-
rently in: Hum Immunol. 2005;66:170–210, Int J Immunogenet.
2005;32:19-69. Tissue Antigens. 2005;65:1-55.
20. Maiers M, Schreuder GMT, Lau M, et al. Use of a neural
network to assign serologic specificities to HLA-A, -B and
-DRB1 allelic products. Tissue Antigens. 2003;62:21-47.
21. Hurley CK, Setterholm M, Lau M, et al. Hematopoietic stem
cell donor registry strategies for assigning search determinants
and matching relationships. Bone Marrow Transplant. 2004;33:
443-450.
22. Maiers M, Setterholm M. HapLogic: the NMDP Registry
match algorithm. Hum Immunol. 2006;67:S127.
23. Hurley CK, Fernandez-Vina M, Hildebrand WH, et al. A high
degree of HLA disparity arises from limited allelic diversity:
analysis of 1775 unrelated bone marrow transplant donor-
recipient pairs. Hum Immunol. 2007;68:30-40.
24. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of
HLA class I and class II high-resolution matching on outcomes
of unrelated donor bone marrow transplantation: HLA-C mis-
matching is associated with a strong adverse effect on transplan-
tation outcome. Blood. 2004;104:1923-1930.
25. Hurley CK, Baxter-Lowe LA, Logan B, et al. National Marrow
Donor Program HLA-matching guidelines for unrelated mar-
row transplants. Biol Blood Marrow Transplant. 2003;9:610-615.
26. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-
recipient HLA matching contributes to the success of unrelated
donor marrow transplantation. Blood. 2007;110:4576-4583.
27. Wade JA, Hurley CK, Takemoto SK, et al. HLA mismatching
within or outside of cross-reactive groups (CREGs) is associated
with similar outcomes after unrelated hematopoietic stem cell
transplantation. Blood. 2007;109:4064-4070.
